Lee-Huang S, Huang P, Huang P; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).
Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. WePeA5651.
New York University School of Medicine, New York, United States
Background: Many AIDS patients use olive leaf extract (OLE) to strengthen the immune system, relieve chronic fatigue, treat KS and HSV, and reduce the side effects of HAART. However, little is known about the anti-HIV activity of OLE and whether it interacts with HAART drugs. This imperils patients who use OLE along with prescription HIV drugs. Thus, investigations on the anti-HIV properties of OLE and its interactions with HIV drugs are of great significance and urgently needed. Methods: Anti-HIV activity was assayed by syncytia formation and p24 expression. MTT assay was used to measure HIV-induced cytopathic effect. Cytotoxicity was evaluated by the MTT assay on uninfected cells. Cellular targets were identified by cDNA microarrays and proteomics. The interaction between OLE and HAART was carried out using a checkerboard design. A modified version of Prichard and Shipman's MacSynergy II was used to analyze the assay results. Results: OLE inhibits acute infection and cell-to-cell transmission of HIV-1. It demonstrates dose-dependent inhibition of syncytia formation and p24 expression, with EC50's of 0.3 mug/ml. OLE is not toxic to uninfected target cells over a 10,000-fold concentration range. cDNA microarrays demonstrate that HIV-1 infection modulates the expression profile of cellular genes involved in cell cycle regulation, apoptosis, and cytokine signaling. Treatment with OLE reverses these changes. Combination antiviral assays demonstrate that OLE exhibits synergistic interactions with both AZT and 3TC. The synergism between OLE and 3TC is about 10-fold greater than that between OLE and AZT. Conclusion This is the first characterization of the anti-HIV activity of OLE. Our results demonstrate synergism between OLE and HAART. This information should help in rational design of HIV treatment regimens that incorporate OLE. We also systematically identify cellular targets associated with infection and OLE treatment. These results may offer new targets for treatment. This publication was made possible by Grant Number RO1 AT001383-01, NCCAM, NIH.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Antiviral Agents
- HIV Infections
- HIV Seropositivity
- HIV-1
- Humans
- Lamivudine
- Zidovudine
Other ID:
UI: 102283585
From Meeting Abstracts